NCT04996550View on ClinicalTrials.gov

Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction

Not yet recruitingOBSERVATIONAL
Enrollment

5,600

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

January 2, 2028

Study Completion Date

December 18, 2028

Conditions
Chronic Heart Failure
Interventions
DRUG

Carvedilol

To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.

DRUG

Metoprolol Succinate

To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.

Trial Locations (1)

5000

Department of Cardiology, Odense University Hospital, Odense

All Listed Sponsors
lead

Odense University Hospital

OTHER

NCT04996550 - Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction | Biotech Hunter | Biotech Hunter